Penumbra (NYSE: PEN) and iRadimed Corporation (NASDAQ:IRMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitabiliy, risk and dividends.
This is a summary of current recommendations and price targets for Penumbra and iRadimed Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Penumbra presently has a consensus price target of $95.00, suggesting a potential upside of 12.96%. iRadimed Corporation has a consensus price target of $12.00, suggesting a potential upside of 19.40%. Given iRadimed Corporation’s higher possible upside, analysts clearly believe iRadimed Corporation is more favorable than Penumbra.
Institutional & Insider Ownership
69.0% of Penumbra shares are owned by institutional investors. Comparatively, 15.9% of iRadimed Corporation shares are owned by institutional investors. 22.0% of Penumbra shares are owned by company insiders. Comparatively, 60.1% of iRadimed Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Penumbra has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, iRadimed Corporation has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
Valuation and Earnings
This table compares Penumbra and iRadimed Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Penumbra||$278.61 million||10.15||-$2.82 million||($0.21)||-400.48|
|iRadimed Corporation||$24.35 million||4.41||$4.51 million||$0.24||41.88|
iRadimed Corporation has higher revenue, but lower earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than iRadimed Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares Penumbra and iRadimed Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
iRadimed Corporation beats Penumbra on 8 of the 13 factors compared between the two stocks.
Penumbra Company Profile
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
iRadimed Corporation Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with our FREE daily email newsletter.